Relay Therapeutics (RLAY) Gains from Investment Securities (2021 - 2022)

Relay Therapeutics' (RLAY) quarterly Gains from Investment Securities came in at -$4.6 million in Q1 2022, down 649.64% on a QoQ basis from $836000.0 in Q4 2021.

Relay Therapeutics (RLAY) Gains from Investment Securities (2021 - 2022) Analysis & Trends

Relay Therapeutics (RLAY) has 2 years of Gains from Investment Securities data on file, last reported at -$4.6 million in Q1 2022.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Relay Therapeutics 3.31 Bn 3.31 Bn -

Historic Data

Download Data
DateValue
Mar 31, 2022 -4.60 Mn
Mar 31, 2022 -4.60 Mn
Dec 31, 2021 836,000.00
Dec 31, 2021 836,000.00